|Day Low/High||225.02 / 227.56|
|52 Wk Low/High||166.30 / 226.55|
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif.
Additional FOURIER Analysis Shows Lowering LDL-C With Repatha Did Not Impair Patient-Reported Cognition
New Registry, cvMOBIUS, Will Assess Lipid Therapies and Five-Year Cardiovascular Outcomes in 8,500 High-Risk Patients With a Recent Atherosclerotic Cardiovascular Disease Event
A study of analyst recommendations at the major brokerages shows that Amgen Inc is the #71 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.
Shares of biopharma giant Amgen have rallied more than 30% since their summer lows and recently hit all-time highs. Investors should now be cautious in the short term due to a strong fundamental resistance level.
New Analyses From the Landmark Repatha® (Evolocumab) FOURIER Cardiovascular Outcomes Study Evaluate Clinical Efficacy and Outcomes in Diverse High-Risk Patient Populations
We feel we are finally getting our chance to get bigger in this still very much beaten down and inexpensive biopharmaceutical stock.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
U.S. stock futures rise ahead of a U.S. jobs report that is expected to show a notable slowdown in U.S. job creation in October; Exxon Mobil, Chevron, Alibaba and AbbVie report earnings; Pinterest shares fall sharply after the company misses third-quarter revenue estimates.
Shares of pharmaceutical giant Celgene slip after receiving a downgrade from analysts at Baird, despite posting better-than-expected quarterly results.
Shares of biotech firm rocket in after-hours trading.
Amgen to Acquire 20.5% Stake in BeiGene for Approximately $2.7 Billion in Cash
According to the charts, the drugmaker should break out to new highs.
Jim Cramer says not having enough time, and having too much government regulation, have more impact on the future revenue streams of companies than does the Federal Reserve.
Publication Showcases how First-to-Clinic Investigational AMG 510 Exploits a Cryptic Groove of the Previously Undruggable KRAS Protein Surface
These stocks are priced for total imperfection. That's just what you want.
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Repatha Original List Price Option Will be Discontinued Effective Dec. 31, 2019
THOUSAND OAKS, Calif., Oct.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.